1. Articles in category: Treatment

    1-24 of 223 1 2 3 4 5 6 7 8 9 10 »
    1. In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

      In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

      J Control Release. 2018 Jul 03;285:162-171

      Authors: Yavuz B, Zeki J, Coburn JM, Ikegaki N, Levitin D, Kaplan DL, Chiu B

      Abstract High-risk neuroblastoma requires surgical resection and multi-drug chemotherapy. This study aimed to develop an extended release, implantable and degradable delivery system for etoposide, commonly used for neuroblastoma treatment.

      Read Full Article
    2. An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma.

      An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma.

      Oncotarget. 2018 Jun 26;9(49):29082-29096

      Authors: Tesson M, Vasan R, Hock A, Nixon C, Rae C, Gaze M, Mairs R

      Abstract Targeted radiotherapy of metastatic neuroblastoma using the somatostatin receptor (SSTR)-targeted octreotide analogue DOTATATE radiolabelled with lutetium-177 (177Lu-DOTATATE) is a promising strategy.

      Read Full Article
    3. P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).

      P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).

      Apoptosis. 2018 Jun 29;:

      Authors: Hua Z, Zhan Y, Zhang S, Dong Y, Jiang M, Tan F, Liu Z, Thiele CJ, Li Z

      Read Full Article
    4. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

      A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

      Novel druggable targets have been discovered in neuroblastoma (NB), paving the way for more effective treatments. However, children with high-risk NB still show high mortality rates prompting for a search of novel therapeutic options. Here, we aimed at repurposing FDA-approved drugs for NB treatment by performing a high-content screening of a 349 anticancer compounds library.

      Read Full Article
      Mentions: Treatment
    5. Predictive Modeling of Neuroblastoma Growth Dynamics in Xenograft Model After Bevacizumab Anti-VEGF Therapy.

      Predictive Modeling of Neuroblastoma Growth Dynamics in Xenograft Model After Bevacizumab Anti-VEGF Therapy.

      Bull Math Biol. 2018 Jun 14;:

      Authors: He Y, Kodali A, Wallace DI

      Abstract Neuroblastoma is the leading cause of cancer death in young children. Although treatment for neuroblastoma has improved, the 5-year survival rate of patients still remains less than half.

      Read Full Article
      Mentions: Treatment
    6. Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.

      Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.

      J Natl Compr Canc Netw. 2018 Jun;16(6):683-691

      Authors: Eterovic AK, Maher OM, Chandra J, Chen K, Huse J, Zaky W

      Abstract Metachronous neoplasms have rarely been reported in patients with neuroblastoma.

      Read Full Article
      Mentions: ALK
    7. Children with neuroblastoma have an elevated risk of long-term psychological difficulties

      A new study reveals that paediatric neuroblastoma patients are at elevated risk for long-term psychological impairment.

      In addition, those who experience such impairment as they get older tend to require special education services and to not go on to...

      Read Full Article
      Mentions: Treatment
    8. President Signs STAR Act for Kids' Cancers.

      President Signs STAR Act for Kids' Cancers.

      Cancer Discov. 2018 Jun 07;:

      Authors:

      Abstract On June 5, President Donald Trump signed the Childhood Cancer Survivorship, Treatment, Access and Research Act, which aims to support pediatric cancer research by expanding the collection of patient biospecimens and records, improving surveillance, and investigating pediatric survivorship.

      PMID: 29880581 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Treatment
    9. Rigorous study finds widely used treatment for infection fails young cancer patients

      A treatment designed to reduce bloodstream infections due to central venous catheters that had worked well in lab studies and is commonly used around the world, but had not been rigorously tested, failed to protect young cancer patients from recurring or...

      Read Full Article
      Mentions: Treatment
    10. Rigorous study finds widely used treatment for infection fails young cancer patients

      Rigorous study finds widely used treatment for infection fails young cancer patients

      ( St. Jude Children's Research Hospital ) St. Jude Children's Research Hospital found ethanol-lock therapy failed to prevent new or recurring infections in cancer patients with central venous catheters and was associated with increased complications.

      Read Full Article
      Mentions: Treatment
    11. NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies

      NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies

      The NCI-MATCH precision medicine clinical trial has reached a milestone with the release of results from several study treatment arms. Findings from three arms were released at the 2018 ASCO annual meeting, adding to findings from one arm released in 2017.

      Read Full Article
    12. Clinical significance of MYCN amplification in patients with high‐risk neuroblastoma

      Fifty‐one (38%) patients had MYCN amplified tumors, and the remaining 84 (62%) had nonamplified tumors. MYCN amplification was associated with abdominal primary site, less differentiated pathology, higher levels of lactate dehydrogenase and neuron‐specific enolase (NSE), lower vanillylmandelic acid level, and larger primary tumor volume at diagnosis. MYCN amplification was associated with a better early response (faster reduction of primary tumor volume and NSE level).

      Read Full Article
      Mentions: MYCN NSE
    13. Cancer Treatment and End-of-Life Care.

      Cancer Treatment and End-of-Life Care.

      J Palliat Med. 2018 May 16;:

      Authors: Sinha S, Matharu JK, Jacob J, Palat G, Brun E, Wiebe T, Segerlantz M

      Abstract AIM: To study to what extent tumor-specific treatment (chemo- or radiotherapy) was given during the last 30 days in life and to examine how many of the patients were referred to a specialized palliative care unit (PCU), at a low-resource governmental hospital in India.

      Read Full Article
    14. Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.

      Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.

      BMC Cancer. 2018 May 11;18(1):560

      Authors: Kunnimalaiyaan S, Schwartz VK, Jackson IA, Clark Gamblin T, Kunnimalaiyaan M

      Abstract BACKGROUND: Neuroblastoma (NB) is a devastating disease. Despite recent advances in the treatment of NB, about 60% of high-risk NB will have relapse and therefore long-term event free survival is very minimal.

      Read Full Article
    15. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

      Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

      Expert Opin Biol Ther. 2018 May 04;:

      Authors: Shum T, Kruse RL, Rooney CM

      Abstract INTRODUCTION: Cancer therapy has been transformed by the demonstration that tumor-specific T-cells can eliminate tumor cells in a clinical setting with minimal long-term toxicity.

      Read Full Article
    16. MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN.

      MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN.

      Oncotarget. 2018 Apr 06;9(26):18160-18179

      Authors: Roth SA, Hald ØH, Fuchs S, Løkke C, Mikkola I, Flægstad T, Schulte J, Einvik C

      Abstract Neuroblastoma is the most common diagnosed tumor in infants and the second most common extracranial tumor of childhood. The survival rate of patients with high-risk neuroblastoma is still very low despite intensive multimodal treatments.

      Read Full Article
      Mentions: MYCN
    17. Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors.

      Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors.

      Cancer Cell Int. 2018;18:63

      Authors: Aveic S, Pantile M, Polo P, Sidarovich V, De Mariano M, Quattrone A, Longo L, Tonini GP

      Abstract Background: A growing field of evidence suggests the involvement of oncogenic receptor tyrosine kinases (RTKs) in cell transformation.

      Read Full Article
    18. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

      Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

      Int J Clin Oncol. 2018 Apr 26;:

      Authors: Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H, Tajiri T, Nakagawara A, Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)

      Read Full Article
    19. A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy.

      A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy.

      Mol Cancer Ther. 2018 Apr 25;:

      Authors: Sidarovich V, De Mariano M, Aveic S, Pancher M, Adami V, Gatto P, Pizzini S, Pasini L, Croce M, Parodi F, Cimmino F, Avitabile M, Emionite L, Cilli M, Ferrini S, Pagano A, Capasso M, Quattrone A, Tonini GP, Longo L

      Read Full Article
    1-24 of 223 1 2 3 4 5 6 7 8 9 10 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles